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It’s Not You,
It’s Me
(Your Genes)
by Gillian Heckler
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“Just as cancer invades the body, depression invades the psyche. Just as we
keep working to find cures for deadly cancers, we need to find ways to help
people overcome the depression that cuts short too many lives”
-Jill Harper, MD

Outcome Disparities of Medications
Patient 1:

Patient 2:

There was no denying that something more than
circumstances was playing a role in my depression.
I went to my doctor, explained my symptoms and
walked out with a prescription for an antidepressant
that day. I stopped thinking about the medicine
and the fact that I was taking it. As time went on,
I noticed subtle changes like having more energy,
and thinking more stably. When I watched movies
I actually laughed aloud and my interactions with
people were less anxiety-filled. I surrounded myself
with my family, found a new job that I really liked and
started a new life. I also found a psychiatrist who I
was very honest with and came to genuinely trust.
Together we decided I should switch to a different
medicine, Prozac. The first antidepressant worked,
but there were some effects that never quite went
away. The new medicine worked perfectly. The year
since I started medication for my depression has
brought me a new life. I have a job I love, and I am
closer than ever to my family. Every once in a while,
I flirt with stopping my medicine. Then I think of my
life prior to Prozac, and I walk to my medicine cabinet
to make sure I am fully stocked. For now, medication
helps me to live the life I want, a life that I am proud
of, and I have no doubt starting medication was the
best decision for my family and I.1

I started going back to therapy and seeing a
psychiatrist. I was prescribed one antidepressant, but
I felt far from ‘normal,’ so I decided to try Prozac. The
first few weeks were fine, and then I started to get really
bad fatigue. I’d try to spend as much time in bed to rest
before work, but then I’d still feel like a spacey zombie
once I got there. It felt like being day-drunk without the
alcohol. My head felt thick and cloudy and my memory
was super off and I had to set a million reminders out of
fear of messing up at work and in life. It was exhausting.
My doctor had me try taking the Prozac at night before
bed, but that only slightly minimized the fatigue. I had
to sleep 12 to 16 hours a day, and it made my behavior
more erratic. Last week, I felt like I was going to pass
out at work and ended up going to the ER because
it was so bad. I stopped taking it since, and though I
can definitely feel my major depression coming back,
it’s almost comforting because the brain fog and fatigue
had gotten so extreme. There’s a lot of trial and error
and ‘shopping around’ when it comes to mental health,
so hopefully, I will eventually find something that works
for me.2

Both of these patients struggle
from the same disorder. Both of
these individuals took the same
antidepressant, Prozac. Yet their
experiences in response to this
medication resulted in dramatically
different outcomes. Why do
medications have such varying
effects for the same disorder?

Does One Size Really
Fit All?
When a ten-year-old boy who is
four foot six and a 50-year-old man

who is six foot three try on the same
“one size fits all” suit, the suit will
be ill-fitting on at least one of them.
Creating and finding that perfect
fit is not so simple. Even if people
have the same goal, of appearing
clean cut or formal, the clothing
item needed will vary person to
person. People have drastically
different body compositions. So,
confining all people who want to
dress up into the same sized suit
will create a haphazard effect. A
tailored approach is a more efficient
way to create the perfect fit that

caters to an individual’s needs, both
for clothing and pharmaceutical
treatments.

The Future is Here
Fortunately, a groundbreaking
method now exists that can use
our genetic information to help
formulate
precise
treatments.
Next
Generation
Sequencing
(NGS) is an exciting technological
advancement
of
the
21st
century that will transform our
understanding of cells and our
approach to treating diseases.
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Figure 1. Genes are sections of DNA that code for RNA, which will determine an individual’s unique
traits.15

These innovative machines allow
researchers to sequence strands
of RNA. DNA is a material that
contains the information to build
and maintain our cells. DNA is
read, or transcribed, into this RNA
material. Genes are sequences of
DNA that code for functions which
determine our unique traits (Figure
1). Through sequencing we can
study individual cells and precisely
identify which genes contribute
to diseases, like Major Depressive
Disorder (MDD).
We can compare DNA to all
of the possible services that the
tailor can perform, from hemming
the length of jackets to taking in
the waist of pants. Then, we can
think of RNA as the messenger
to communicate which particular
service is selected. The uniquely
tailored suit that results as the final
product can represent our unique
traits. So even if all individuals have
the same services to order from,
their end product can be drastically
different. We all practically have
the same DNA, but the unique
traits made from this DNA differ
from person to person. The NGS
technology considerably advances
our understanding of genes, the
segments of DNA, that contribute
to many disorders in need of
superior treatments, including
MDD.
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An Invisible Pain

Articulating
mental
pain
presents a challenge because
the phenomena is intangible.
Therefore, it sometimes does not
seem as legitimate compared to
other physical disorders. Everyone
may not fit into the same sample
size suit, and everyone may not
have the same gene activity
or concentration of chemicals.
Neurotransmitters—dopamine,
serotonin, and norepinephrine—
are chemicals that send signals
and communicate with your brain.
These chemicals in particular
regulate mood and help make
you feel good. Low levels of these
chemicals are considered hallmarks
of MDD. This chemical imbalance
could be an aftermath of gene
dysregulation that sequencing can
help us pinpoint. Recognizing the
legitimate biochemical alteration
occurring in MDD can help validate
an individual’s experience and
encourage people to seek help for
management of the disorder.
The Diagnostic and Statistical
Manual of Mental Disorders
(DSM-5) describes MDD as being
characterized by distinct changes in
affect and cognition with episodes
lasting for at least two weeks.3 MDD
can arise at different time points
for different people. A breadth
of factors may contribute to the

onset of MDD, including economic
pressures, social environments,
trauma,
neurobiology,
and
genetics. Not only can MDD affect
an individual’s mental health, but
it can also alter physical health,
inducing headaches, appetite
changes, and disruptive sleep
patterns.3 Individuals with MDD
can experience varying symptoms,
but often feelings of hopelessness
and internal criticism pervade.
The specific reasoning for the
development of MDD remains
ambiguous due to the complex
interactions between an individual’s
genetic
makeup
and
their
environment. Understanding the
causal mechanisms for MDD can
allow for more concrete diagnostics,
and therefore implement more
effective therapeutic offerings.
While the disorder can involve
behavioral, psychological, and
cultural factors, there is substantial
evidence that the disorder relates
to DNA with a 40% chance of
heritability.4 Additionally, if an
antidepressant has been effective
for a family member, there is a
higher likelihood that it will be
more effective in comparison to an
antidepressant prescribed by the
general trial and error method.5
A more intentional practice of
assigning patients to medication
based on their unique genetic
composition can offer necessary
transformation to the treatment
process of MDD.

Do You Have to Do
Drugs?
Medications are a major relief
for many individuals who experience
this disorder. While pharmaceuticals
are a fundamental option, there
are also alternative routes for
treatments such as psychotherapy,
and dietary changes. According
to the most decorated Olympian,
Michael Phelps, who struggles with
depression, speaking to a therapist
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offers him stability, growth, and
support in his darkest of days.6 We
do not expect individuals to manage
their diabetes or coronary artery
disease on their own. Why would
we expect individuals to manage
MDD on their own? Psychotherapy
is an invaluable approach to
manage MDD, particularly in
conjunction with medication. With
a trained psychologist, individuals
can confide in a professional to
understand their feelings and
behaviors, while also gaining
coping skills. A popular type
of psychotherapy is cognitive
behavioral therapy, where the
therapist and patient work together
on constructive ways to modify and
improve behaviors and beliefs.7
Acquiring help through therapy
exemplifies strength by prioritizing
health and seeking personal
growth.
Incorporating
nutritional
elements, like omega 3-fatty acids
found in foods such as cold-water
fish and flax seed, has the potential
to alleviate symptoms of MDD.
In nations where the population
consumes large quantities of
fish, depression rates are lower.8
Furthermore, saffron extract has
shown to inhibit a decrease in
serotonin levels, improving MDD
symptoms in adult patients.9
Another promising option, vitamin
D
supplementation,
provides
therapeutic relief by promoting
extracellular levels of serotonin.10
Consistent physical exercise
can also increase chemicals in the
brain, like dopamine and serotonin.
A misconception persists that only
vigorous exercise serves as an
effective treatment.
In reality, individuals who
engage in moderate physical
activity, such as taking 30-minute
strolls three times a week, reduce
the risk of experiencing major
depressive episodes.11 Integrative
styles of yoga that incorporate
meditation and breathwork have

also been shown to be quite
valuable.
Mindfulness
based
interventions
show
effective
results of reducing depression,
anxiety, and stress.12 However,
holistic approaches take ample
amounts of time to take effect
and may not initially be realistic
for individuals with severe cases
of MDD who already reside in a
very fragile mental state. Many
of these approaches could offer
maximum efficacy as an adjunct to
more traditional pharmacological
approaches.

Shortcomings of
Pharmacological
Options
If you have a chronic headache,
why would you not take an
ibuprofen? If someone experiences
chronic depression, similar logic
follows with taking antidepressants.
Finding medication can often be
associated with a “quick fix”. In
reality, quite an extensive amount
of time is expended to properly
allocate the most efficacious
medication for each patient. The
process of doctors distributing
prescriptions occurs by a trial-anderror method. This method is like
going shopping and not looking
at the size on the tag beforehand.
Then you go to the dressing room
and go through the hassle of

trying on multiple poorly fitting
outfits. Unfortunately, you leave
feeling displeased because none
of them fit, as none of them were
intentionally chosen for you.
Currently,
a
symptombased approach is often utilized
to treat people with MDD.5
Physicians will try to take into
account a patient’s symptoms to
speculate if one medication may
be more suitable than another to
minimize undesirable side effects.
Unfortunately, this method does
not suffice for people who require
more immediate relief, as not every
patient has the luxury of time to
try three different medications.
Altering medications can also
pose challenges since weaning off
the prescriptions can sometimes
emulate flu-like symptoms. People
alter their medications due to the
unbearable side effects. Some of
the side effects make it difficult
to adequately function with
overwhelming feelings of fatigue
and a sense of overall numbness.
In the one size fits all scenario,
you have an item that allows you
to pass the requirements of a
formal dress code, but you are far
from feeling comfortable. From
constantly having to pull up your
pants to having your sleeves drag
throughout your food, these side
effects are far from desirable. In
addition to adverse side effects,
the medication can also take
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several weeks and even months
for patients to feel an effect. If you
take your suit to get tailored for
an upcoming event, but the suit
isn’t ready until a month after your
event, was it even worth it?
Another shortcoming with
current
medication
involves
individuals initially experiencing
or developing resistance to the
treatment medications offered.
To counter this issue, individuals
have to either wait even longer
for an effect, increase dosages,
or take multiple antidepressants.
These approaches can often feel
confusing and tumultuous for
patients as months pass without
experiencing any improvement.
Current
antidepressants
can
provide critical relief to subside
internal pain but desperately
require further innovation.

The Power of
Sequencing
Different expression levels of
genes are often responsible for
cells’ behaviors in diseases.13 Gene
expression can be considered to

have an on/off switch. Variances
in gene expression are due to
the instructional code of DNA
producing different quantities of
functional products. By comparing
gene expression activity of patients
with MDD to people that are
considered healthy, we can observe
the discrepancies of gene activities
between the two groups. Using
the novel technology of NGS,
we can perform single cell RNA
sequencing (scRNAseq), which
clusters or groups cells with similar
characteristics. Established in 2009,
this scRNAseq method is still in its
infancy stages in the science world
and offers great transformative
promise. An analogy for scRNAseq
is the classification process of
desserts. Dessert is an overarching
category that comprises many
subcategories. Characteristics of
the desserts, whether they have
chocolate or fruit, or whether
they are baked or frozen, can
help us classify each dessert. For
instance, ice cream, gelato, and
frozen yogurt may comprise one
cluster, while cobbler, crumble, and
crisp may comprise another. The

same process happens in order to
distinguish cell subtypes based on
gene expression characteristics.
The first ever scRNAseq study
of MDD published in 2020 reveals
that 16 unique subtypes have
distinct gene activities in patients
with MDD (Figure 2).14 Instead of a
uniform disorder, MDD may be an
umbrella construct with multiple
biologically distinct disorders that
each require unique treatments.
Neurons, which are the primary
cells that transmit information
throughout the brain, make up
six of the cell subtypes. Nonneuronal cells, which are cells that
help support and maintain the
nervous system, make up four of
the cell subtypes. Each cluster
is considered a cell subtype and
has similar gene expressions
to other cells in that subtype.
Deconvoluting the complexities
of different cell subtypes in the
nervous system with scRNAseq
offers great potential to develop
novel medicine. This method can
help us discover and then target
specific genes in cell subtypes with
greater precision. If we discover
that only a particular subtype has
discrepancies in MDD patients
compared to control patients, we
can target that particular subtype.
Rather than distributing medication
to all cells throughout the entire
brain and potentially harming
healthy cells, targeting one cell
subtype will increase effectiveness.
We have the power to develop
superior treatments aiming to
minimize the treatment resistance,
late onset period, and side effects
of current medications.

The Science Behind
Happiness
Figure 2: In MDD, scRNAseq reveals 16 different subtypes that are represented in distinct clusters.
Each point indicates a single cell that has similar characteristics to other cells in that cluster. The
characteristics of each cell are determined by gene activity levels. Original image by Gillian Heckler..
Created in BioRender.
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The majority of dysregulated
genes in MDD patients are
downregulated.14 When genes
are downregulated in a cell,
production of that gene product
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decreases. Sometimes the effect
of downregulation does not
have a negative implication. For
example, we often do not see
adults with naturally occurring
blonde hair. If an individual is
born with blonde hair, those
genes are often downregulated
by the time that individual reaches
adulthood. While this example of
downregulation does not have any
dire consequences, downregulation
of genes that regulate nerve cells
can result in harmful ramifications
on the psyche.
Out of the 16 subtypes
discovered, two cell subtype
clusters had the most prominent
changes in patients with MDD
in comparison to the control.14
The first subtype, composed of
excitatory neurons, was termed
Excitatory 7 (EX7). The cluster EX7
involves a gene that regulates
neuronal excitability. Excitatory
cells fire and send messages to
other areas of the brain. In MDD,
downregulation
of
excitatory
neurons is quite common. In order
for our neurotransmitters like
serotonin to bind to its receptors,
we need to have excitation. The
other prominent group is a nonneuronal cell type labeled OPC2.
This subtype, OPC2, is suspected
to be involved in brain plasticity.
Brain plasticity signifies the brain’s
ability to change and adapt to the
environment and new experiences.
In MDD brains, genes that regulate
plasticity are turned off. One of
the defining characteristics of this
OPC2 cluster is the downregulation
of the PRNP gene (Figure 3). The
absence of the PRNP gene is
implicated in a lack of cell division
and brain plasticity.
If you only want the waist
taken in, rather than shrinking your
entire suit in the dryer, you can only
alter that one section and prevent
the disruption of functional
components. This approach holds
for targeting genes in subtypes

Figure 3: The happy face cells are found in the control patients, and the sad face cells are found in
MDD patients. The cell subtypes, OPC2 and EX7 have lower gene expressions in comparison to
the healthy controls. The gene PRNP is expressed at very low levels in the OPC2 subtype. Genes
involved in excitation are expressed at very low levels in the EX7 subtype of MDD patients. Original
image by Gillian Heckler. Created in BioRender.

rather than your entire system.
Potentially increasing the levels of
the PRNP gene in only the particular
OPC2 subtype could serve as an
effective treatment for MDD.

Hope is Here
A suit precisely designed for
an individual will help ensure a
good fit. The same logic applies
for designing precise treatments
for MDD patients. ScRNAseq
can shed light on the ambiguous
complexities of MDD. Instead of
continuing on the prescription
method of trial and error, we
can take a more methodical

approach to target downregulated
genes with greater precision.
With societal acknowledgments
of MDD and advancements in
genetic research, we have so much
potential to improve the quality of
life for those struggling with MDD.
By raising awareness on topics, we
can foster empathy, rather than fear
unfamiliarity. The disorder may not
be something that you “defeat”,
but people can be empowered
with tools to support their health.
Implementing novel therapeutics
and destigmatizing MDD can allow
for the vast majority of people to
live fulfilling and vibrant lives.
■

“There is hope, even when your brain tells you there isn’t”
-John Green
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